Johnson & Johnson announced the appointment of several senior leaders to the Company’s Executive Committee. Separately, the Company announced that Michael Sneed, Executive Vice President, Global Corporate Affairs and Chief Communication Officer, will be retiring on April 1, 2022, the statement said. As previously announced, Alex Gorsky will serve as Executive Chairman of Johnson & Johnson and…
Johnson & Johnson announced that Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. Following the transition of the Chief Executive Officer role, Duato will also…
Johnson & Johnson announced that Dr. Nadja West, a retired U.S. Army lieutenant general and former U.S. Army Surgeon General has been appointed to its Board of Directors. Commenting on the appointment, Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said, “I am pleased to welcome Dr. Nadja West to Johnson & Johnson’s…
Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. According to the press release, the initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety…
Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; and the rapid scaling of the company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The company expects to initiate human clinical studies…